Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

641.O1.6 Animal Models of CLL

Sunday, December 7, 2008: 4:30 PM-6:00 PM
2001-2003-2014-2016 - West (Moscone Center)
Moderators:
J. Brice Weinberg, MD and Amy J Johnson, PhD
4:30 PM
The DLEU2/Mir-15a/Mir-16-1 Locus, Commonly Deleted in B-Cell Chronic Lymphocytic Leukemia (CLL), Controls B-Cell Compartment Expansion and Its Deletion Leads to CLL in MiceClinically Relevant Abstract

Ulf Klein1*, Marie Lia1*, Qiong Shen1*, Paula M Smith1*, Hongyan Tang1*, Tongwei Mo1*, Marta Crespo1*, Rachael Siegel1*, Govind Bhagat2* and Riccardo Dalla-Favera3

1Institute for Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
2Institute for Cancer Genetics, Department of Pathology and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
3Institute for Cancer Genetics, Department of Pathology and Genetics & Development and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY

4:45 PM
A Human Hematopoietic Environment and Autologous T-Cell Growth Support Proliferation of Chronic Lymphocytic Leukemia B Cells in Immune-Deficient Mice

Davide Bagnara1*, Matthew Kaufman2*, Xiao J. Yan, MD, PhD1, Kanti Rai3* and Nicholas Chiorazzi, MD4

1The Feinstein Institute for Medical Research, Manhasset, NY
2Long Island Jewish Medical Center, New Hyde Park, NY
3OP Svc-Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY
4Experimental Immunology, The Feinstein Institute for Medical Research - NSLIJHS, Manhasset, NY

5:00 PM
Macrophage Migration Inhibitory Factor (MIF) Promotes the Development of Murine Chronic Lymphocytic Leukemia (CLL)

Nina Reinart1*, Malgorzata Ciesla1*, Cornelia Rudolph, MD2*, Astrid Stein, MD3*, Guenter Krause, PhD1*, Brigitte Schlegelberger, MD2, Michael Hallek, MD1* and Guenter Fingerle-Rowson, MD, PhD1*

1Dpt. of Internal Medicine I, University Hospital Cologne, Cologne, Germany
2Inst. of Cell & Molecular Pathology, Hannover Medical School, Hannover, Germany
3Dpt. of Pathology, University Hospital Cologne, Cologne, Germany

5:15 PM
Constitutive Baff Signalling Plays a Key Role in CLL Development by Promoting Tumor Cell Survival

Thomas Enzler, MD, PhD1*, Weizhou Zhang, PhD2*, Arnon P. Kater, MD, PhD3*, George F. Widhopf II, PhD1*, Carlo M. Croce, MD4, Michael Karin, PhD5* and Thomas J. Kipps, MD, PhD6

1Moores Cancer Center, University of California San Diego and Academic Medical Center Amsterdam, La Jolla, Netherlands
2Laboratory of Gene Regulation and Signal Transduction, School of Medicine, University of California San Diego
3Moores Cancer Center, University of California San Diego and Academic Medical Center Amsterdam, La Jolla, CA
4The Ohio State University Comprehensive Cancer Center, Columbus, OH
5Laboratory of Gene Regulation and Signal Transduction, School of Medicine, University of California San Diego, La Jolla
6Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA

5:30 PM
Hematopoietic Stem Cells Are Primarily Involved in Pathogenesis of Chronic Lymphocytic Leukemia

Yoshikane Kikushige, MD1*, Toshihiro Miyamoto, MD, PhD2, Tadafumi Iino, MD3*, Fumihiko Ishikawa, MD, PhD4* and Koichi Akashi, MD, PhD5

1Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan
2Ctr. for Cellular & Mole. Med., Kyushu University Hospital, Fukuoka, Japan
3Dana-Farber Cancer Institute, Cancer Immunology and AIDS, Boston, MA
4Rsrch. Unit for Human Disease Models, RIKEN Rsrch. Ctr. for Allergy & Immunology, Yokohama, Japan
5Dana-Farber Cancer Inst., Boston, MA

5:45 PM
A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction

Alan G. Ramsay, PhD1, Gullu Gorgun, PhD2, Tobias A.W. Holderried2*, David Zahrieh, MS2*, Fenglong Liu, PhD2*, John Quackenbush, PhD2*, Carlo M. Croce, MD3 and John G. Gribben, MD, DSc1*

1Ctr. for Medical Oncology, Institute of Cancer, Barts & London Sch. of Med., London, United Kingdom
2Dana-Farber Cancer Institute, Boston, MA
3The Ohio State University Comprehensive Cancer Center, Columbus, OH

*signifies non-member of ASH